Independent, client-informed recognition
CDMO Leadership Awards
The CDMO Leadership Awards recognize contract development and manufacturing organizations based on direct feedback from biopharma companies that have worked with them. Recognition reflects real-world outsourcing performance, not submissions or self-nominations.
The 2027 survey is open now. If you work with CDMOs, share your experience.
About the awards
Recognition based on verified client feedback.
Each year, biopharma professionals involved in outsourcing decisions rate the CDMOs they've worked with. The awards recognize the organizations those clients rate highest for overall performance and partnership.
CDMO of the Year
The highest level of client-rated recognition within each modality and size category, based on aggregated survey results.
Best in Class
Calculated from the same survey data. Recognizes top performance in specific attributes like project management, cultural fit, and scaling support.
Strengthening rigor and transparency
Starting with the 2026 awards, the program is conducted in research partnership with the Tufts Center for the Study of Drug Development. Tufts CSDD provides independent oversight of survey design, respondent validation, and analysis. CDMOs can't self-nominate, submit materials, or influence scoring.
2027 awards survey
Share your CDMO experience.
Tufts CSDD is collecting candid feedback from pharmaceutical and biotechnology professionals about their experiences with their CDMO partners. Results will be used to recognize CDMOs that provide outstanding relationships and services. All responses are confidential and reported only in the aggregate.
Do you work with CDMOs?
If you work at a pharmaceutical or biotechnology company and have firsthand experience with the CDMOs you evaluate, we'd love to hear from you. Every response helps.
Are you a CDMO?
You can invite your eligible clients to share their experience. The survey toolkit has the survey link, a ready-to-send invitation, and the participation guidelines.
Integrity comes first
- Only eligible clients should complete the survey, based on their own firsthand experience.
- CDMO employees shouldn't take the survey or respond on behalf of clients.
- No directing scores, duplicate submissions, or incentives tied to participation or ratings.
Tufts CSDD reviews submissions for integrity. CDMOs tied to improper activity may be disqualified.
Methodology
How the awards are determined.
The methodology prioritizes independence, consistency, and client-led evaluation, so recognition reflects real-world performance rather than submissions, nominations, or promotional activity.
Independent research oversight
Tufts CSDD is responsible for:
- Survey design and structure
- Respondent qualification and validation
- Statistical analysis and methodological rigor
Life Science Connect administers the program and publishes the findings but doesn't select winners or influence scoring.
Respondent eligibility
Survey responses come from qualified biopharma professionals who:
- Are directly involved in outsourcing decisions or oversight
- Have worked with the CDMO they're evaluating within the past 18 to 24 months
- Evaluate only CDMOs they've personally worked with
Respondents may evaluate multiple CDMOs if they meet these criteria for each relationship.
What CDMOs can't do
- Self-nominate
- Submit materials
- Decide who qualifies to take the survey
- Influence scoring or outcomes
Program independence
CDMOs aren't eligible to sponsor the program. Sponsorship is limited to non-CDMO organizations and doesn't influence survey design, scoring, shortlists, or award recipients.
Survey structure and supporting inputs
Primary metric
The primary award metric is a 0 to 10 likelihood-to-recommend score for each CDMO a respondent has worked with during the eligibility period. It reflects the respondent's overall assessment of the CDMO as an outsourcing partner.
Supporting performance inputs
Respondents also rate CDMOs across performance dimensions, including development capabilities, manufacturing performance, delivery and reliability, and ongoing support and collaboration.
They also identify best-in-class performance for attributes such as technical expertise, on-time delivery, innovation, facilities and infrastructure, and quality systems. These inputs add context but don't replace the primary recommendation score.
Scoring model and thresholds
The awards use a proprietary scoring model that blends likelihood-to-recommend scores, supporting satisfaction ratings, and best-in-class attribute rankings.
Minimum thresholds apply, including a minimum number of qualified responses per CDMO and minimum score thresholds within each modality and cohort. Only CDMOs that meet both response-count and score thresholds are eligible for recognition.
Modalities, cohorts, and size categories
CDMOs are evaluated within defined modalities and regional cohorts. These may include, but aren't limited to, biologics, cell and gene therapy, small-molecule API, and small-molecule dosage forms.
CDMOs are grouped into two revenue-based categories, Large and Small/Mid-Sized, so companies are evaluated among similar peers. $1B in CDMO revenue is the threshold between the two groups.
Continuity and evolution
The methodology builds on the recommendation-based framework used in prior years while adding independent research oversight. Core principles stay the same: client-led evaluation, verified respondent qualification, clear scoring thresholds, and separation between survey results and commercial activity.
Our research partner
Research conducted in partnership with Tufts CSDD
The Tufts Center for the Study of Drug Development is an independent, academic, nonprofit research group at Tufts University. Since 1976, Tufts CSDD has produced robust, data-driven assessments, analysis, and insight focused on improving drug development performance, efficiency, and economics.
Tufts CSDD independently manages respondent qualification and survey analysis for the CDMO Leadership Awards.
2026 finalists and winners
Congratulations to the 2026 honorees.
The 2026 finalists and winners were selected based on direct feedback from biopharma decision makers and independently analyzed by Tufts CSDD. Thank you to the sponsors who helped make this year's celebration possible.
Large and Small/Mid-Sized categories use $1B in CDMO revenue as the threshold.
CDMO of the Year
Biologic CDMO of the Year
Large CDMOs
WuXi Biologics
Finalists: AbbVie, Samsung Biologics
Small/Mid-Sized CDMOs
Eurofins
Finalists: KBI Biopharma, Pharmaron
Cell & Gene Therapy CDMO of the Year
Large CDMOs
MilliporeSigma
Finalists: Lonza, Recipharm
Small/Mid-Sized CDMOs
Aldevron
Finalist: Ajinomoto Bio-Pharma Services
Small Molecule API CDMO of the Year
Large CDMOs
Lonza
Finalists: Almac, WuXi STA
Small/Mid-Sized CDMOs
Asymchem
Finalists: Esteve CDMO, Pharmaron
Small Molecule Finished Dose CDMO of the Year
Sponsored by MasterControl
Large CDMOs
Vetter Pharma
Finalists: Lonza, WuXi STA
Small/Mid-Sized CDMOs
Bend Bioscience
Finalists: Corden Pharma, Pharmaron
Fill-Finish CDMO of the Year
Large CDMOs
AbbVie
Finalists: Vetter Pharma, WuXi Biologics
Small/Mid-Sized CDMOs
KBI Biopharma
Finalists: Eurofins, Syngene International
Best in Class
Top performers in each Best in Class attribute by modality and company size. Select a category to see results.
Large Biologic
| Attribute | Winner | Finalists |
|---|---|---|
| Analytical Services | WuXi Biologics | MilliporeSigma, Lonza |
| Overall Staff | WuXi Biologics | AbbVie, Samsung Biologics |
| Project Management | WuXi Biologics | Samsung Biologics, AbbVie |
| Cultural Fit | Samsung Biologics | AbbVie, WuXi Biologics |
| Technology Use | MilliporeSigma | WuXi Biologics, AbbVie |
| Scaling Support | WuXi Biologics | AbbVie, Samsung Biologics |
Large Cell & Gene Therapy
| Attribute | Winner | Finalists |
|---|---|---|
| Analytical Services | MilliporeSigma | Recipharm, FUJIFILM Biotechnologies |
| Overall Staff | MilliporeSigma | Recipharm, Thermo Fisher Scientific |
| Project Management | MilliporeSigma | Recipharm, Lonza |
| Cultural Fit | MilliporeSigma | Lonza, Recipharm |
| Technology Use | MilliporeSigma | Recipharm, Lonza |
| Scaling Support | Recipharm | Thermo Fisher Scientific, MilliporeSigma |
Large Small Molecule API
| Attribute | Winner | Finalists |
|---|---|---|
| Analytical Services | Lonza | MilliporeSigma, WuXi STA |
| Overall Staff | Lonza | MilliporeSigma, Curia |
| Project Management | Lonza | Curia, Almac |
| Cultural Fit | Lonza | Almac, MilliporeSigma |
| Technology Use | MilliporeSigma | Lonza, Almac |
| Scaling Support | Curia | WuXi STA, Almac |
Large Small Molecule Finished Dose
| Attribute | Winner | Finalists |
|---|---|---|
| Analytical Services | Vetter Pharma | WuXi STA, Lonza |
| Overall Staff | Vetter Pharma | Lonza, Catalent |
| Project Management | Vetter Pharma | Lonza, Catalent |
| Cultural Fit | Lonza | Vetter Pharma, Catalent |
| Technology Use | Vetter Pharma | Lonza, Thermo Fisher Scientific |
| Scaling Support | WuXi STA | Catalent, Thermo Fisher Scientific |
Small/Mid-Sized Biologic
| Attribute | Winner | Finalists |
|---|---|---|
| Analytical Services | Simtra BioPharma Solutions | Pharmaron, KBI Biopharma |
| Overall Staff | Simtra BioPharma Solutions | KBI Biopharma, IDT Biologika |
| Project Management | Simtra BioPharma Solutions | Abzena, KBI Biopharma |
| Cultural Fit | KBI Biopharma | AGC Biologics, Eurofins |
| Technology Use | Simtra BioPharma Solutions | KBI Biopharma, Abzena |
| Scaling Support | Simtra BioPharma Solutions | AGC Biologics, PCI Pharma Services |
Small/Mid-Sized Cell & Gene Therapy
| Attribute | Winner | Finalists |
|---|---|---|
| Analytical Services | Aldevron | AGC Biologics, IDT Biologika |
| Overall Staff | Aldevron | IDT Biologika, Ajinomoto Bio-Pharma Services |
| Project Management | Aldevron | IDT Biologika, Ajinomoto Bio-Pharma Services |
| Cultural Fit | Aldevron | IDT Biologika, Ajinomoto Bio-Pharma Services |
| Technology Use | Aldevron | IDT Biologika, Cellipont |
| Scaling Support | Aldevron | IDT Biologika, Ajinomoto Bio-Pharma Services |
Small/Mid-Sized Small Molecule API
| Attribute | Winner | Finalists |
|---|---|---|
| Analytical Services | Alcami | AGC Pharma Chemicals, Pharmaron |
| Overall Staff | AGC Pharma Chemicals | Veranova, Asymchem |
| Project Management | Veranova | AGC Pharma Chemicals |
| Cultural Fit | AGC Pharma Chemicals | Veranova, Esteve |
| Technology Use | AGC Pharma Chemicals | Esteve, Asymchem |
| Scaling Support | AGC Pharma Chemicals | Asymchem, Veranova |
Small/Mid-Sized Small Molecule Finished Dose
| Attribute | Winner | Finalists |
|---|---|---|
| Analytical Services | Asymchem | Bend Bioscience, Alcami |
| Overall Staff | Grifols International S.A. | Asymchem, Corden Pharma |
| Project Management | Grifols International S.A. | Corden Pharma, Asymchem |
| Cultural Fit | Grifols International S.A. | Corden Pharma, Asymchem |
| Technology Use | Corden Pharma | Asymchem, Pharmaron |
| Scaling Support | Grifols International S.A. | Asymchem, Corden Pharma |
2026 Jury Awards
Jury Awards were selected by an independent panel of industry leaders in 2026. They aren't part of the 2027 program.
| Award | Winner | Finalists |
|---|---|---|
| Most Innovative CDMO, Small Molecule | Esteve CDMO | Carbogen Amcis, Upperton Pharma Solutions, Veranova |
| Most Innovative CDMO, Biologics | FUJIFILM Biotechnologies | AGC Biologics, Just-Evotec Biologics, Rentschler Biopharma |
| Most Innovative CDMO, Cell & Gene Therapy | OXB | NorthX Biologics, ProBioGen, Viralgen |
| Best New or Relaunched CDMO | Lotte Biologics | Ardena, Axplora, Biovectra, Minaris Advanced Therapies, Rezon Bio, Simtra BioPharma Solutions |
| Best CDMO Management Team | Siegfried | 3PBiovian, Dottikon, Grand River Aseptic Manufacturing, IDT Biologika |
| Best Private Equity Team Supporting the CDMO Industry | GHO Capital | 1315 Capital, EQT, Permira, Thomas H. Lee Partners, Warburg Pincus |
| Sustainability Leadership Award | Samsung Biologics | Boehringer Ingelheim BioXcellence, Lonza, Thermo Fisher Scientific, Vetter Pharma |
2026 Lifetime Achievement Award
Derek Hennecke, recognized for more than three decades of leadership in the CDMO industry.
Sponsorship
Connect with senior CDMO and biopharma decision makers.
The CDMO Leadership Awards bring together senior CDMO and biopharma leaders during DCAT Week and key global industry moments. Sponsorship supports the program and recognition events while preserving the independence of the awards.
Why sponsors take part
- Targeted visibility among senior executives attending DCAT Week and related events
- A curated audience responsible for outsourcing strategy, manufacturing, external partnerships, and supply chain decisions
- Brand alignment with recognized CDMO performance
- Post-event visibility across Life Science Connect and Outsourced Pharma channels
2027 sponsorship paths
- Title sponsorship of the awards ceremony and reception, for one company seeking elevated visibility and priority access
- Award sponsorships for CDMO of the Year and Best in Class, including presenting the award on stage
- Experience sponsorships tied to high-traffic onsite moments
- Brand presence, media, and custom options for focused visibility during and after the event
The 2027 ceremony takes place Wednesday, March 17, 2027, at The Pool in New York City during DCAT Week. Early commitment opportunities are available for select sponsorships.
Representative companies and roles
Registrants span executive leadership, business development, manufacturing, procurement, and external supply functions, with most attendees at the executive, vice president, and director level.
- AGC Biologics | Chief Executive Officer
- Ajinomoto Bio-Pharma Services | President & COO
- Aenova | Chief Commercial Officer
- BIOVECTRA | Chief Commercial Officer
- Oxford Biomedica | Chief Business Officer
- Thermo Fisher Scientific | President, Commercial Operations
- Piramal Pharma Solutions | Chief Operating Officer
- Siegfried | Chief Scientific Officer
- WuXi Biologics | Senior Vice President, Global CMC
- Lonza | EVP, Head of Mammalian Business Unit
- Porton Pharma Solutions | SVP, Business Development, Europe
- Avid Bioservices | Senior Director, Business Development
- PCI Pharma Services | VP, Business Development, North America
- Aenova | VP, Global Business Development
- Bionova Scientific | VP, Business Development
- Nanoform | VP, Business Development
- Biogen | Director, External Network Strategy
- BIOVECTRA | Director, Procurement
- CordenPharma International | Senior Platform Director
- Esteve | Global Head of Commercial Operations & Strategy
- Boehringer Ingelheim Biopharmaceuticals | Director, Key Account Management
- Pfizer CentreOne | Director, Network Strategy
Next steps
If you work with a Life Science Connect account manager, reach out to them to talk through fit, availability, and timing. Full details on levels, deliverables, and timelines are in the prospectus.
Download the 2027 sponsorship prospectus (PDF)
Sponsorship doesn't affect survey methodology, scoring, shortlists, or winners. We can't provide survey access or accept submissions or materials from CDMOs.
Questions about the survey or the awards? Reach out to your Life Science Connect account manager.
Take the 2027 survey FAQs Contact Survey toolkit for CDMOs
Life Science Connect | 210 W Kensinger Drive, Suite 500, Cranberry Township, PA 16066 | 724-940-7555
Follow along: Outsourced Pharma on LinkedIn
CDMO Leadership Awards · Presented by Outsourced Pharma and Life Science Connect
Research conducted in partnership with Tufts CSDD